Do analysts recommend PBYI or PLYX?

Polaryx Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 314.63%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer PBYI or PLYX?

In the previous week, Puma Biotechnology and Puma Biotechnology both had 2 articles in the media. Puma Biotechnology's average media sentiment score of 0.94 beat Polaryx Therapeutics' score of 0.31 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PLYX or PRTC?

Polaryx Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 314.63%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, PLYX or PRTC?

Polaryx Therapeutics has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A -$0.05 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is PLYX or PRTC more profitable?

Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A PureTech Health N/A N/A N/A

Is PLYX or EVMN more profitable?

Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Evommune N/A N/A N/A

Does the media refer more to PLYX or EVMN?

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for Evommune. Polaryx Therapeutics' average media sentiment score of 0.31 beat Evommune's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, RZLT or PLYX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Polaryx Therapeutics N/A N/A N/A -$0.05 N/A

Is RZLT or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Polaryx Therapeutics N/A N/A N/A

Does the media favor RZLT or PLYX?

In the previous week, Rezolute had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 6 mentions for Rezolute and 2 mentions for Polaryx Therapeutics. Rezolute's average media sentiment score of 0.80 beat Polaryx Therapeutics' score of 0.31 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CGC or PLYX?

Polaryx Therapeutics has a consensus target price of $8.50, indicating a potential upside of 314.63%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to CGC or PLYX?

In the previous week, Canopy Growth had 9 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 11 mentions for Canopy Growth and 2 mentions for Polaryx Therapeutics. Canopy Growth's average media sentiment score of 1.12 beat Polaryx Therapeutics' score of 0.31 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Polaryx Therapeutics (PLYX) Competitors

$2.05 -0.06 (-2.84%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.03 -0.02 (-0.98%)

As of 07/24/2026 07:15 PM Eastern

Compare

PLYX vs. PBYI, PRTC, EVMN, RZLT, and CGC

Should you buy Polaryx Therapeutics stock or one of its competitors? MarketBeat compares Polaryx Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Polaryx Therapeutics include Puma Biotechnology (PBYI), PureTech Health (PRTC), Evommune (EVMN), Rezolute (RZLT), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry.

How does Polaryx Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Puma Biotechnology has a net margin of 10.69% compared to Polaryx Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Polaryx Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 314.63%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Puma Biotechnology and Puma Biotechnology both had 2 articles in the media. Puma Biotechnology's average media sentiment score of 0.94 beat Polaryx Therapeutics' score of 0.31 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.3% of Puma Biotechnology shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Puma Biotechnology has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.78	$31.11M	$0.48	16.63
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Summary

Puma Biotechnology beats Polaryx Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Polaryx Therapeutics compare to PureTech Health?

Polaryx Therapeutics (NASDAQ:PLYX) and PureTech Health (NASDAQ:PRTC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Polaryx Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 314.63%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polaryx Therapeutics has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
PureTech Health	N/A	N/A	N/A

0.0% of PureTech Health shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Polaryx Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 0 mentions for PureTech Health. Polaryx Therapeutics' average media sentiment score of 0.31 beat PureTech Health's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
PureTech Health	Neutral

Summary

Polaryx Therapeutics beats PureTech Health on 5 of the 8 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Evommune?

Polaryx Therapeutics (NASDAQ:PLYX) and Evommune (NYSE:EVMN) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Polaryx Therapeutics has higher earnings, but lower revenue than Evommune. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Evommune	$13M	31.48	-$68.87M	-$9.50	N/A

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for Evommune. Polaryx Therapeutics' average media sentiment score of 0.31 beat Evommune's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Polaryx Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 314.63%. Evommune has a consensus price target of $45.63, suggesting a potential upside of 301.63%. Given Polaryx Therapeutics' higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Evommune	N/A	N/A	N/A

Summary

Evommune beats Polaryx Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Rezolute had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 6 mentions for Rezolute and 2 mentions for Polaryx Therapeutics. Rezolute's average media sentiment score of 0.80 beat Polaryx Therapeutics' score of 0.31 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Polaryx Therapeutics' return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Rezolute presently has a consensus target price of $9.38, suggesting a potential upside of 87.88%. Polaryx Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 314.63%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Rezolute beats Polaryx Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

3.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Polaryx Therapeutics has lower revenue, but higher earnings than Canopy Growth. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$284.60M	1.40	-$190.29M	-$0.59	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Polaryx Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -75.27%. Polaryx Therapeutics' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-75.27%	-26.95%	-17.20%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics has a consensus target price of $8.50, indicating a potential upside of 314.63%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Canopy Growth had 9 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 11 mentions for Canopy Growth and 2 mentions for Polaryx Therapeutics. Canopy Growth's average media sentiment score of 1.12 beat Polaryx Therapeutics' score of 0.31 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Canopy Growth and Polaryx Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$96.41M	$3.11B	$7.24B	$12.26B
Dividend Yield	N/A	15.21%	40.99%	9.79%
P/E Ratio	-41.00	13.16	23.62	23.64
Price / Sales	N/A	2,709.07	132.14	89.45
Price / Cash	N/A	25.90	165.01	59.64
Price / Book	N/A	9.39	12.77	6.07
Net Income	N/A	-$34.07M	$120.21M	$331.99M
7 Day Performance	-10.09%	0.44%	-0.98%	-0.63%
1 Month Performance	-11.26%	0.09%	-2.00%	-2.00%
1 Year Performance	N/A	9.86%	9.75%	13.62%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	3.352 of 5 stars	$2.05 -2.8%	$8.50 +314.6%	N/A	$96.41M	N/A	N/A	11
PBYI Puma Biotechnology	0.9871 of 5 stars	$8.53 +1.5%	N/A	+134.7%	$427.55M	$228.40M	17.77	200	News Coverage Positive News
PRTC PureTech Health	N/A	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
EVMN Evommune	3.2097 of 5 stars	$12.16 +3.8%	$45.63 +275.2%	N/A	$421.77M	$10M	N/A	45	Positive News
RZLT Rezolute	3.2737 of 5 stars	$4.61 +5.5%	$9.38 +103.4%	-15.0%	$420.80M	N/A	N/A	40	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. PBYI, PRTC, EVMN, RZLT, and CGC

How does Polaryx Therapeutics compare to Puma Biotechnology?

Summary

How does Polaryx Therapeutics compare to PureTech Health?

Summary

How does Polaryx Therapeutics compare to Evommune?

Summary

How does Polaryx Therapeutics compare to Rezolute?

Summary

How does Polaryx Therapeutics compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. PBYI, PRTC, EVMN, RZLT, and CGC

How does Polaryx Therapeutics compare to Puma Biotechnology?

Is PBYI or PLYX more profitable?

Do analysts recommend PBYI or PLYX?

Does the media prefer PBYI or PLYX?

Do institutionals & insiders hold more shares of PBYI or PLYX?

Which has higher valuation and earnings, PBYI or PLYX?

Summary

How does Polaryx Therapeutics compare to PureTech Health?

Do analysts prefer PLYX or PRTC?

Which has stronger valuation & earnings, PLYX or PRTC?

Is PLYX or PRTC more profitable?

Do insiders & institutionals hold more shares of PLYX or PRTC?

Does the media prefer PLYX or PRTC?

Summary

How does Polaryx Therapeutics compare to Evommune?

Which has better valuation & earnings, PLYX or EVMN?

Does the media refer more to PLYX or EVMN?

Do analysts prefer PLYX or EVMN?

Is PLYX or EVMN more profitable?

Summary

How does Polaryx Therapeutics compare to Rezolute?

Does the media favor RZLT or PLYX?

Is RZLT or PLYX more profitable?

Which has stronger earnings and valuation, RZLT or PLYX?

Do insiders and institutionals hold more shares of RZLT or PLYX?

Do analysts prefer RZLT or PLYX?

Summary

How does Polaryx Therapeutics compare to Canopy Growth?

Do institutionals and insiders believe in CGC or PLYX?

Which has better valuation and earnings, CGC or PLYX?

Is CGC or PLYX more profitable?

Do analysts recommend CGC or PLYX?

Does the media refer more to CGC or PLYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools